ArticleScientific reports2021
AST to Platelet Ratio Index (APRI) is an easy-to-use predictor score for cardiovascular risk in metabolic subjects.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 68 citations in OpenAlex.
- Trial
- Evaluation of the Safety and Efficacy of SOF/VEL Treatment and Pre-treatment of TAF in Patients with Chronic Hepatitis B Virus/Hepatitis C Virus Coinfection: A Multicenter Study.Journal of clinical and translational hepatology · 2026Article
- Fibrotic NASH Index (FNI) Is Associated with Long-Term Mortality in Individuals with Type 2 Diabetes and MASLD.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Effects of orlistat on APRI and FIB-4 scores in patients with obesity: a retrospective observational study.BMC endocrine disorders · 2026Observational
- Abdominal Adipose Tissue Fibrosis as an Obesity Biomarker in Clinical Practice.Obesity facts · 2026Article
- Noninvasive liver fibrosis assessment in metabolic dysfunction-associated steatotic liver disease.World journal of hepatology · 2026Review
- I-FABP, citrulline and non-invasive liver dysfunction indices in patients with depression - cross-sectional study results.BMC gastroenterology · 2026Article
- Hematological abnormalities in clinically diagnosed non-alcoholic steatohepatitis: prevalence, clinical correlates, and fibrosis risk in a case-control study from Qatar.Frontiers in medicine · 2026Article
- Aspartate aminotransferase-to-platelet ratio index as a novel predictor of early mortality in heat stroke patients: a multi-centre retrospective study.Annals of medicine · 2025Article
- Synergistic effects of body fat percentage and C-reactive protein triglyceride-glucose index on cardiovascular disease risk: a Chinese cohort study.Scientific reports · 2025Article
- Remnant cholesterol, low-density lipoprotein cholesterol and atherosclerotic cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: a cohort study.Lipids in health and disease · 2025Article
- Predictive value of preoperative MELD-Na score versus APRI for postoperative outcomes after infrainguinal bypass in peripheral artery disease.Langenbeck's archives of surgery · 2025Article
- Observational
- Improving cardiovascular risk stratification: the role of abdominal obesity in predicting MACEs.Cardiovascular diabetology · 2025Article
- Useful Biomarkers for Preeclampsia: Evaluating the Diagnostic Potential of FIB-4 and FIB-5 Indices.Diagnostics (Basel, Switzerland) · 2025Article
- An Exploration of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Platelet Ratio Index (APRI) Scores with Dysglycemia and Diabetic Retinopathy: The Beichen Eye Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Regular extra-virgin olive oil intake independently associates with lower abdominal obesity.Frontiers in nutrition · 2025Article
- Predictive factors of body weight loss in patients with type 2 diabetes treated with GLP-1 receptor agonists: a 52-week prospective real-life study.Frontiers in endocrinology · 2025Observational
- Associations among serum levels of MMP-1, MMP-2, and METAVIR fibrosis score in patients with nonalcoholic fatty liver disease.Gastroenterology and hepatology from bed to bench · 2025Article
- Predicting Severe COVID-19 Outcomes in the Elderly: The Role of Systemic Immune Inflammation, Liver Function Tests, and Neutrophil-to-Lymphocyte Ratio.Healthcare (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Visceral obesity is characterized by a low-grade inflammatory systemic state that contributes to the genesis of non-alcoholic fatty liver disease (NAFLD), frequently associated with liver fibrosis. Non-invasive serum markers have recently emerged as reliable, easy-to-use scores to predict liver fibrosis. NAFLD is often linked to metabolic and cardiovascular risk. Thus, in this cross-sectional study, we investigated in a population of 1225 subjects if AST to Platelet Ratio Index (APRI), one of the non-invasive liver fibrosis serum markers, can predict cardiovascular risk (CVR). APRI has been previously validated as an efficient score to predict liver fibrosis in viral hepatitis patients with a cut-off of 0.5 for fibrosis and 1.5 for cirrhosis. Our study showed that APRI significantly correlates with CVR and determines, when elevated, a significant increase in CVR for both genders, especially females. This spike in CVR, observed when APRI is elevated, is relatively high in patients in the age of 51-65 years, but it is significantly higher in younger and premenopausal women, approaching risk values usually typical of men at the same age. Taken together, our data highlighted the role of APRI as a reliable predictor easy-to-use score for CVR in metabolic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.